Rezolute, Inc. Quarterly report pursuant to sections 13 or 15(d)

Quarterly report pursuant to sections 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2014

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Contractual Life
Outstanding, June 30, 2012		-	$	-		-
Granted		1,508,334	$	4.50
Outstanding, June 30, 2013		1,508,334	$	4.50		4.6
Granted		2,680,000	$	3.12
Outstanding, March 31, 2014		4,188,334	$	3.62		4.6

Exercisable at March 31, 2014		1,174,190	$	4.50		3.9

Schedule Of Warrants Issued To Agents Activity [Table Text Block]

Warrants- AntriaBio issued warrants to agents and note holders in conjunction with the closing of its convertible notes payable as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2012		-	$	-		-
Warrants issued to placement agents		41,424	$	1.98
Warrants issued to placement agent		233,334	$	1.50
Warrants issued to placement agent		18,334	$	4.95
Outstanding, June 30, 2013		293,092	$	1.80		4.1
Warrants issued to note holders		225,259	$	1.89
Warrants issued to note holders		3,657,205	$	2.04
Warrants issued to related party		39,117	$	7.50
Warrants issued in private placement		3,716,522	$	2.34
Outstanding, March 31, 2014		7,931,195	$	2.19		3.0

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions were as follows:

Expected volatility	93% - 97	%
Risk free interest rate	0.78% - 1.46	%
Warrant term (years)	3 - 5
Dividend yield	0	%